S-glycoside Patents (Class 514/24)
  • Patent number: 10258640
    Abstract: A method of inhibiting quorum sensing in Pseudomonas aeruginosa is provided. The method comprises contacting Pseudomonas aeruginosa with a gold(I) thiolate complex in an amount effective to inhibit quorum sensing in the Pseudomonas aeruginosa. Use of the method for the treatment or prevention of damage or disease associated with quorum sensing and/or biofilm formation in a subject, or for the treatment of biofilm and/or for inhibiting biofilm formation is also provided.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: April 16, 2019
    Assignees: NANYANG TECHNOLOGICAL UNIVERSITY, NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Michael Christian Givskov, Shu Sin Chng, Liang Yang, Zhen Wei Leon Tan, Ziyan Hong
  • Patent number: 10071042
    Abstract: The present invention aims to provide an external dermal composition for anti-ageing, which prevents or improves apparent skin problems such as age-related or senescent wrinkles, fine wrinkles, saggings, spots, etc., as well as maintaining or enhancing the skin barrier functions. The object is solved by providing an external dermal agent for anti-ageing, which contains as an effective ingredient(s) one or more members selected from the group consisting of adenosine N1-oxide 5?-phosphate, analogs thereof, and their salts.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: September 11, 2018
    Assignee: HAYASHIBARA CO., LTD.
    Inventors: Keizo Kohno, Satomi Miyata, Toshiharu Hanaya, Shigeharu Fukuda
  • Patent number: 9504704
    Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: November 29, 2016
    Assignee: DOW PHARMACEUTICAL SCIENCES, INC.
    Inventors: Yunik Chang, Gordon J. Dow, Radhakrishnan Pillai
  • Patent number: 9023811
    Abstract: The present invention relates to a composition comprising a high glucosinolate Cruciferous vegetable (such as a high glucosinolate broccoli) having a high level of glucosinolate and/or at least one derivative thereof for use in the treatment or prevention of a cardiovascular disease or for use in promoting heart and/or cardiovascular health.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: May 5, 2015
    Assignee: Plant Bioscience Limited
    Inventor: Richard Mithen
  • Patent number: 9018176
    Abstract: The present invention generally relates to compositions containing chemical compounds and compositions and pharmaceutical formulations of the compounds which increase the expression of total hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other blood cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia, and other blood cell deficiencies and blood disorders. The invention also relates to methods for administering these compositions to subjects and for use as medical aids for the treatment and prevention of blood and other disorders.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: April 28, 2015
    Inventors: Susan Perrine, Douglas V. Faller
  • Publication number: 20150111840
    Abstract: Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture.
    Type: Application
    Filed: May 30, 2014
    Publication date: April 23, 2015
    Inventors: Jinling CHEN, Nasser N. NYAMWEYA, Kenneth K. H. ONG
  • Patent number: 8993740
    Abstract: The present invention relates to a method for preparation of the tetrasaccharide lacto-N-neotetraose (LNnt, formula (I)) especially in large scale, as well as intermediates in the synthesis, a new crystal form (polymorph) of LNnt, and the use thereof in pharmaceutical or nutritional compositions.
    Type: Grant
    Filed: February 21, 2011
    Date of Patent: March 31, 2015
    Assignee: Glycom A/S
    Inventors: István Bajza, Gyula Dekany, Károly Ágoston, Ignacio Figuero-Pérez, Julien Boutet, Markus Hederos, Ferenc Horváth, Piroska Kovács-Pénzes, Lars Kröger, Christoph Röhrig, Andreas Schroven, Ioannis Vrasidas, Péter Trinka, László Kalmár, Irme Kovács, Sándor Demkó, Ágnes Ágoston, Christian Risinger
  • Publication number: 20150080324
    Abstract: The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 19, 2015
    Inventors: Gavin David Heffernan, David Penman Jacobus, Guy Alan Schiehser, Hong-Ming Shieh, Wenyi Zhao
  • Publication number: 20150064118
    Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
    Type: Application
    Filed: September 15, 2014
    Publication date: March 5, 2015
    Inventors: Krister THURESSON, Fredrik TIBERG, Markus JOHANSSON, Ian HARWIGSSON, Fredrik JOABSSON, Markus JOHNSSON
  • Patent number: 8962573
    Abstract: The invention relates to conjugates of products of interest including glycoproteins, nanoparticles, and imaging agents and of compounds of the general formula (1): that target the cation-independent mannose 6-phosphate receptor with a high affinity. The invention also relates to their applications, for instance in enzyme replacement therapies.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: February 24, 2015
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre National de la Recherche Scientifique—CNRS, Universite de Montpellier 1, Universite de Montpellier 2 Sciences et Techniques
    Inventors: Marcel Garcia, Alain Morere, Magali Gary-Bobo, Martine Cerutti, Khaled El Cheikh, Ilaria Basile, Philippe Nirde
  • Publication number: 20150032045
    Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 29, 2015
    Inventors: Rafael Yuste, Roberto Etchenique, Luis Baraldo
  • Patent number: 8937050
    Abstract: Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: January 20, 2015
    Assignees: The Johns Hopkins University, Kennedy Krieger Institute, Inc.
    Inventors: Paul Talalay, Andrew W. Zimmerman, Kirby D. Smith
  • Publication number: 20150017099
    Abstract: The invention provides methods and compositions for the diagnosis, prognosis and treatment of respiratory tract diseases. Specifically, the invention provides diagnosis, prognosis and treatment of respiratory infections using bitter and sweet taste signal transduction pathways. In one aspect, the invention relates to a method for treating a respiratory infection by administering a composition to the respiratory tract of a subject in an amount capable of activating bitter taste signaling and/or inhibiting sweet taste signaling. The composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract. In another aspect, the invention relates to a composition for treatment of a respiratory infection. Such composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract.
    Type: Application
    Filed: January 25, 2013
    Publication date: January 15, 2015
    Inventors: Noam A. Cohen, Robert J. Lee, Danielle R. Reed
  • Publication number: 20150018290
    Abstract: The present invention generally relates to compositions containing chemical compounds and compositions and pharmaceutical formulations of the compounds which increase the expression of total hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other blood cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia, and other blood cell deficiencies and blood disorders. The invention also relates to methods for administering these compositions to subjects and for use as medical aids for the treatment and prevention of blood and other disorders.
    Type: Application
    Filed: December 2, 2011
    Publication date: January 15, 2015
    Applicant: Trustees of Boston University
    Inventors: Susan Perrine, Douglas V. Faller
  • Publication number: 20150011486
    Abstract: Glycosylated antitumor ether lipids (GAELs) are effective cytotoxic agents against cancer stem cells. Furthermore, combining GAELs which kill cells by a caspase-independent pathway with agents that kill cells by apoptosis will lead to elimination of the differentiated tumor cells and the undifferentiated cancer stem cells leading to an elimination of the tumor and preventing recurrence.
    Type: Application
    Filed: February 8, 2013
    Publication date: January 8, 2015
    Inventors: Gilbert Arthur, Frank Schweizer, Pranati Samadder, Yaozu Xu
  • Publication number: 20140377357
    Abstract: An inhalation composition for the treatment of bacteria related diseases is provided. The disclosed composition may include a mixture of three or more API(s) and a micronized poloxamer composition. Micronized poloxamer composition may include poloxamer 188 and poloxamer 407. According to an embodiment, an inhalation composition including one or more APIs may be delivered to the respiratory tract by employing inhalation devices, such as inhalers and nebulizers. Antibiotic inhalation composition may provide improved solubility and bioavailability for three or more API(s), such as levofloxacin, betamethasone, and clindamycin. Furthermore, the synergistic effect of micronized poloxamer composition may provide improved solubility and bioavailability of any suitable API.
    Type: Application
    Filed: June 19, 2013
    Publication date: December 25, 2014
    Applicant: Professional Compounding Centers of America
    Inventor: Daniel Banov
  • Publication number: 20140371163
    Abstract: A novel regime or regimen for the treatment of acne related diseases and particularly acne vulgaris includes administering to a patient in need of such treatment a therapeutically effective amount of Differin gel 0.3% (adapalene) in association or combination with a combined clindamycin/benzoyl peroxide gel product such as DUAC®.
    Type: Application
    Filed: March 12, 2014
    Publication date: December 18, 2014
    Applicant: Galderma Research & Development
    Inventors: Lucy COLON, Ronald Gottschalk
  • Patent number: 8901072
    Abstract: The invention relates to derivatives of glycopeptide and lipoglycopeptide antibiotics possessing an altered ionization state with respect to the parent glycopeptide or lipoglycopeptide antibiotic, and having the ability to be regenerated as the parent glycopeptide or lipoglycopeptide antibiotic under physiological conditions. These compounds are useful as antibiotics for the prevention and/or the treatment of bacterial infections.
    Type: Grant
    Filed: August 11, 2010
    Date of Patent: December 2, 2014
    Assignee: The Medicines Company
    Inventors: Adel Rafai Far, Kelly Tanaka, Evelyne Dietrich, Ranga Reddy, Ting Kang
  • Patent number: 8895070
    Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: November 25, 2014
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Yunik Chang, Gordon J. Dow
  • Patent number: 8889733
    Abstract: Artonin I is reported to treat multi-drug resistant Staphlococcus infections.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: November 18, 2014
    Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Atia-tul Wahab, Christian D. A. Fozing, Atta-ur Rahman
  • Publication number: 20140323391
    Abstract: Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject.
    Type: Application
    Filed: March 15, 2014
    Publication date: October 30, 2014
    Applicant: Duke University
    Inventors: Ephraim Tsalik, Vance Fowler, Christopher W. Woods, Joseph E. Lucas, Geoffrey S. Ginsburg, Sun Hee Ahn
  • Patent number: 8871726
    Abstract: The present invention relates to a C-aryl glucoside derivative of Formula (I) below, a preparation method therefor and a use thereof, wherein X, R1, R2, R3, R4, m and n are as defined in specification. The derivative of the present invention is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor associated with glucose reabsorption of bowel or kidney, and has a good urine glucose excreting effect, thus being useful as a therapeutic agent for treating diabetes and related diseases.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: October 28, 2014
    Assignee: Shanghai Allist Pharmaceuticals, Inc.
    Inventor: Huibing Luo
  • Patent number: 8865659
    Abstract: This invention is for the compound containing ginsenoside Rg3 as an active ingredient to prevent and treat Hepatitis C virus infection. Specifically, the ginsenoside Rg3 of this invention demonstrated the predominant antiviral activities and apotosis actions in a dose-dependent manner in the Hepatitis C virus infected cells (Huh 7.5.1). Confirmed that it reduces the levels of TNF-? and thioredoxin significantly, and increases phospho-NF?B. It also demonstrated same effectiveness as PegInterferone alpha-2b(PegIFN a-2b, Hepatitis C therapeutics), and has no cytotoxicity to human bodies. Thus, it may be used safely as an active ingredient of medical/pharmaceutical and health food compounds for preventing or treating Hepatitis C.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: October 21, 2014
    Inventor: Jae-Young Jang
  • Publication number: 20140309178
    Abstract: Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula: the various substituents of which are defined herein.
    Type: Application
    Filed: November 18, 2013
    Publication date: October 16, 2014
    Applicant: LEXICON PHARMACEUTICALS, INC.
    Inventors: Kenneth Gordon CARSON, Nicole Cathleen GOODWIN, Bryce Alden HARRISON, David Brent RAWLINS, Eric STROBEL, Brian ZAMBROWICZ
  • Publication number: 20140303100
    Abstract: This invention pertains to dental care compositions with antimicrobial benefits. In particular, the invention provides for compositions of oral tissue-adherent salts that release biocidal ions on a controlled release basis and thereby provide and maintain an essentially uniform concentration of biocidal ions above the MBC or MIC of the target bacteria at the site of application in the mouth for an extended period of time. The compositions are useful for treating or preventing oral diseases resulting from bacteria, fungal or yeast infections, such as caries, gingivitis, periodontal disease and candidiasis.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 9, 2014
    Inventors: Anthony Errol Winston, Richard F. Stockel, Anthony Joseph Sawyer
  • Publication number: 20140303073
    Abstract: The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 9, 2014
    Applicant: Sarepta Therapeutics, Inc.
    Inventor: Patrick L. Iversen
  • Publication number: 20140303101
    Abstract: This invention pertains to dental care compositions with antimicrobial benefits. In particular, the invention provides for compositions of oral tissue-adherent salts that release biocidal ions on a controlled release basis and thereby provide and maintain an essentially uniform concentration of biocidal ions above the MBC or MIC of the target bacteria at the site of application in the mouth for an extended period of time. The compositions are useful for treating or preventing oral diseases resulting from bacteria, fungal or yeast infections, such as caries, gingivitis, periodontal disease and candidiasis.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 9, 2014
    Inventors: Anthony Errol Winston, Richard F. Stockel, Anthony Joseph Sawyer
  • Publication number: 20140296133
    Abstract: The invention discloses silaanalogs of oxazolidinone compounds, to pharmaceutical compositions and to the synthesis of the oxazolidinone derivatives of formula I. The invention further relates to methods of treating a subject suffering with gram positive pathogens including those resistant to methicillin and vancomycin using the compound(s) or modulation of coagulation properties of blood-clotting cascade or compositions of the oxazolidinone derivatives of the invention.
    Type: Application
    Filed: October 11, 2012
    Publication date: October 2, 2014
    Applicant: Council of Scientific & Industrial Research
    Inventors: Dumbala Srinivasa Reddy, Seetharam Singh Balamkundu, Remya Ramesh
  • Publication number: 20140286876
    Abstract: The present invention, as described above and as further defined by the claims, provides methods of administering an active agent via adhesion of a film to a mucous membrane in the oral cavity of a mammal, as well as and ODF formed therefore. An active agent may be ingested as the ODF dissolves resulting in systemic treatment of the mammal. In additional embodiments, an ODF may provide topical administration of an active agent.
    Type: Application
    Filed: March 28, 2014
    Publication date: September 25, 2014
    Inventor: Andrew L. Skigen
  • Publication number: 20140271921
    Abstract: A topical composition comprises at least 5 wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.
    Type: Application
    Filed: May 28, 2014
    Publication date: September 18, 2014
    Applicant: SLA PHARMA AG
    Inventor: DAVID NIGEL ARMSTRONG
  • Publication number: 20140256658
    Abstract: The present invention describes antibiotic conjugates. These single drug entities are formed connecting one antibiotic with another antibiotic. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita S. Bhat, Ken Chow, LIMING WANG, MICHAEL E. GARST, MAYSSA ATTAR, BRANDON D. SWIFT
  • Publication number: 20140234420
    Abstract: The present invention describes methods and compositions for treating diverse dermatological conditions, including acne and psoriasis, using zein containing nanocarrier devices for topical delivery of methotrexate, retinoic acid and benzoyl peroxide to select targets in the skin.
    Type: Application
    Filed: August 14, 2013
    Publication date: August 21, 2014
    Inventors: Omathanu P. Perumal, Ranjith Kumar Averineni
  • Publication number: 20140235560
    Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
    Type: Application
    Filed: April 23, 2014
    Publication date: August 21, 2014
    Inventors: Yunik Chang, Gordon J. Dow
  • Patent number: 8809305
    Abstract: A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and preferably once a day, a thus effective amount of a topical medicament containing adapalene and benzoyl peroxide, formulated into a pharmaceutically acceptable medium therefor.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: August 19, 2014
    Assignee: Galderma Research & Development
    Inventors: Michael Graeber, Yin Liu, Barbara Gore
  • Publication number: 20140221922
    Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: POLY-MED, INC.
    Inventors: Shalaby W. Shalaby, David Ingram, Georgios Hilas, Sheila Nagatomi
  • Publication number: 20140219996
    Abstract: The present invention provides novel ruthenium compounds of Formula (I): or salts, isomers, hydrates, or solvates thereof, or combinations thereof; wherein E, R1, R2, R3, R4, R5, X1, and X2 are as defined herein, and pharmaceutical compositions thereof. Also provided are methods of use and treatment. Such compounds have been found useful in the treatment of malaria infection. Such compounds may also be useful in the treatment of inflammatory conditions, such as acute lung injury and acute respiratory distress syndrome, which optionally may be associated with a malaria infection.
    Type: Application
    Filed: July 20, 2012
    Publication date: August 7, 2014
    Applicant: ALFAMA- Investigacao e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Ana Pamplona, Gonçalo J.L. Bernardes, Maria M. Mota, Carlos C. Romão
  • Patent number: 8785420
    Abstract: Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: July 22, 2014
    Assignee: Galderma Research & Development
    Inventors: Marie-Line Abou Chacra Vernet, Denis Gross, Christian Loesche, Michel Poncet
  • Publication number: 20140199413
    Abstract: The invention relates to formulations for topical use comprising an antiseborrheic agent and an antimicrobial and/or antibacterial agent for the treatment of inflammatory dermatoses. In particular said formulations comprise melatonin and an antimicrobial or antibacterial agent, can be used in the pharmaceutical, cosmetic/cosmeceutical or dermatological field and are particularly suitable for the treatment of acne and of the clinical symptoms associated thereto.
    Type: Application
    Filed: January 5, 2012
    Publication date: July 17, 2014
    Applicant: NOVAERA S.R.L.
    Inventor: Giorgio Endrici
  • Publication number: 20140200190
    Abstract: Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, wherein the galectin is preferably a galectin-3.
    Type: Application
    Filed: March 17, 2014
    Publication date: July 17, 2014
    Applicant: Galecto Biotech AB
    Inventors: Hakon LEFFLER, Ulf J. NILSSON, Henrik VON WACHENFELDT
  • Publication number: 20140200189
    Abstract: Artonin I is reported to treat multi-drug resistant Staphlococcus infections.
    Type: Application
    Filed: January 14, 2013
    Publication date: July 17, 2014
    Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Atia-tul-Wahab, Christian D.A. Fozing
  • Publication number: 20140186279
    Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 3, 2014
    Applicant: CAMURUS AB
    Inventors: Fredrik JOABSSON, Margareta LINDEN, Krister THURESSON, Fredrik TIBERG
  • Publication number: 20140187503
    Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.
    Type: Application
    Filed: December 2, 2013
    Publication date: July 3, 2014
    Applicant: Hansa Medical AB
    Inventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
  • Publication number: 20140148398
    Abstract: Compounds useful for the treatment of giardiasis are described.
    Type: Application
    Filed: October 12, 2011
    Publication date: May 29, 2014
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Wei Zheng, Catherine Chen, Juan Jose Marugan, Noel Southall, Christopher P. Austin, Andrey Galkin, Liudmila Kulakova, Osnat Herzberg
  • Publication number: 20140134252
    Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
    Type: Application
    Filed: October 28, 2013
    Publication date: May 15, 2014
    Applicant: Dow Pharmaceutical Sciences, Inc.
    Inventors: Yunik Chang, Gordon J. Dow
  • Publication number: 20140135277
    Abstract: Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.
    Type: Application
    Filed: June 25, 2013
    Publication date: May 15, 2014
    Inventors: Bryce Alden HARRISON, Spencer David KIMBALL, Ross MABON, David Brent RAWLINS
  • Patent number: 8703720
    Abstract: Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: April 22, 2014
    Assignee: Galecto Biotech AB
    Inventors: Hakon Leffler, Ulf J. Nilsson, Henrik Von Wachenfeldt
  • Publication number: 20140105967
    Abstract: A stabilized, topical composition for the treatment of acne and other dermatological conditions comprises a liposomal formulation of a retinoid and an antibiotic in which the retinoid is disposed in the lipid phase of the formulation, and the antibiotic is disposed in the aqueous phase so as to be isolated from the retinoid. Lincosamides, such as clindamycin, are one group of antibiotics which may be used in the composition. Tretinoin is one preferred retinoid. Also disclosed are methods for making the compositions and methods for using the composition.
    Type: Application
    Filed: December 16, 2013
    Publication date: April 17, 2014
    Applicant: FERNDALE IP, INC.
    Inventor: Pravin M. Patel
  • Publication number: 20140088028
    Abstract: The invention provides compounds of formula (I) with substituents as specified in Claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to over-expression of O-GlcNAcase or accumulation of O-GlcNac.
    Type: Application
    Filed: March 20, 2012
    Publication date: March 27, 2014
    Inventors: Ramesh Kaul, Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Kun Liu, Harold G. Selnick, Zhongyong Wei, Changwei Mu, Yaode Wang, Xiaona Wang
  • Publication number: 20140080769
    Abstract: The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 20, 2014
    Applicants: The Chancellor, Masters and Scholars of the University of Oxford, The Government of the United States of America, as represented by the Secretary, Department of Healt
    Inventors: Frances Mary Platt, Emyr Lloyd-Evans, Forbes Dennison Porter
  • Patent number: 8663699
    Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: March 4, 2014
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Yunik Chang, Gordon J. Dow